Written and peer-reviewed by physicians—but use at your own risk. Read our disclaimer.

banner image

amboss

Trusted medical answers—in seconds.

Get access to 1,000+ medical articles with instant search
and clinical tools.

Try free for 5 days

Aortic valve stenosis

Last updated: October 7, 2020

Summary

Aortic valve stenosis (AS) is a valvular heart disease characterized by narrowing of the aortic valve. As a result, the outflow of blood from the left ventricle into the aorta is obstructed. This leads to chronic and progressive excess load on the left ventricle and potentially left ventricular failure. The patient may remain asymptomatic for long periods of time; for this reason, AS is often detected late when it first becomes symptomatic (dyspnea on exertion, angina pectoris, or syncope). Auscultation reveals a harsh, crescendo-decrescendo murmur in systole that radiates to the carotids, and pulses are delayed with diminished carotid upstrokes. Echocardiography is the noninvasive gold standard for diagnosis. Patients with mild asymptomatic aortic stenosis are treated conservatively with monitoring and medical management of related conditions (e.g, hypertension). Symptomatic patients, or those with severe aortic valve stenosis, require immediate aortic valve replacement (AVR) as definitive treatment. Options for valve replacement include surgical AVR or transcatheter AVR (TAVR) for patients with high operative risk. Patients with severe AS have a high risk of developing acute complications such as heart failure and cardiogenic shock, which are challenging to manage and often require critical care interventions and expedited surgery or TAVR.

Epidemiology

Epidemiological data refers to the US, unless otherwise specified.

Etiology

The most common etiologies of valvular aortic stenosis include:

Pathophysiology

References:[5][6]

Clinical features

Aortic stenosis may remain asymptomatic for years; , particularly with mild or moderate stenosis. Symptoms usually start to develop when the disease progresses to severe AS, and may present at rest or on exertion.

To remember the three major symptoms of aortic valve stenosis, think: SAD (syncope, angina, dyspnea).

References:[5][7]

Classification

American Heart Association (AHA) staging system [8]

  • Used to monitor disease progression and determine the need for intervention
  • Based on echocardiographic criteria of valve anatomy and hemodynamics
AHA staging for aortic valve stenosis [8]
Stage Definition Aortic valve area (AVA) Transaortic velocity Mean aortic pressure gradient
Stage A aortic valve stenosis At risk of AS 3–4 cm2 < 2.0 m/second < 10 mm Hg
Stage B aortic valve stenosis Progressive AS Mild: 1.5–2.9 cm2 2.0– 2.9 m/second 10–19 mm Hg
Moderate: 1.0–1.4 cm2 3.0–3.9 m/second 20–39 mm Hg
Stage C1 aortic valve stenosis Asymptomatic severe AS (LVEF normal) ≤ 1.0 cm2 ≥ 4.0 m/second ≥ 40 mm Hg
Stage C2 aortic valve stenosis Asymptomatic severe AS (LVEF < 50%)
Stage D aortic valve stenosis Symptomatic severe AS

Diagnostics

Initial evaluation

Echocardiography [8]

Other

Additional evaluation [8]

Low-dose dobutamine stress testing

Exercise stress testing

Exercise stress testing is contraindicated in patients with severe symptomatic AS (stage D).

Cardiac catheterization

Advanced imaging [8][14][15]

Consider the following noninvasive imaging options in the perioperative assessment of patients with severe AS, along with expert consultation. [8][14]

  • Cardiac CT
    • Used in select patients to rule out concomitant CAD if pretest probability is low
    • Can quantify valve calcification
    • Useful for specific measurements required prior to TAVR
  • Cardiac MRI
    • Provides precise information on anatomy and hemodynamics
    • Can be helpful in evaluating severity of AS but is not always available

Differential diagnosis

Treatment

General principles [8]

  • Aortic valve stenosis is a progressive condition and definitive management requires valve replacement.
  • Urgency of valve repair/replacement depends on staging.
    • Symptomatic and/or severe AS: aortic valve replacement usually indicated
    • Asymptomatic or mild-moderate AS: management of medical comorbidities and monitoring echocardiography; some may benefit from early valve replacement [16]
  • Management of acute complications requires individualized and specialized care.

Medical management

Management of medical comorbidities [8]

All patients should be screened and treated for other cardiac risk factors.

Management of acute complications [3][8][16][24]

Prompt critical care specialist consultation and rapid surgical referral are recommended. Patients should receive AVR as soon as possible.

Afterload reduction (e.g., with vasodilators or diuretics) in severe AS may reduce cardiac output enough to compromise systemic and myocardial perfusion. Careful titration is recommended with specialist guidance.

Severe AS compromises coronary perfusion (due to high LV pressure and low pressure in the aortic root). Avoid hypotension as it can cause cardiac ischemia.

Monitoring and prophylactic antibiotics [8]

Aortic valve replacement (AVR) and repair

Indications

  • Symptomatic patients with severe, high-gradient AS (stage D AS)
  • Asymptomatic patients with severe AS and:
  • AVR can also be beneficial for certain patients with moderate (stage B AS) to severe (stage D AS) with specific characteristics.

The presence of exertional symptoms (dyspnea on exertion, angina pectoris, syncope) is an indication for surgery.

Procedure

All patients being considered for TAVR or high-risk surgical AVR should be treated by members of a heart valve team. [8]

  • Surgical AVR
    • Recommended for patients with: [8]
  • Transcatheter AVR (TAVR)
    • Recommended for patients with high or prohibitive surgical risk and predicted survival of > 12 months [8][14]
    • Reasonable alternative for patients with intermediate surgical risk [8]
    • Emergency TAVR may be considered in certain patient groups. [28][29][30]
  • Percutaneous balloon valvuloplasty
    • Indicated in children, adolescents, and young adults without AV calcification [8]
    • Can consider as a bridging intervention in high-risk patients with stage D AS but overall benefit is questionable. [8][31]

Complications of aortic valve replacement [32][33][34]

Antithrombotic therapy after aortic valve replacement

Antithrombotic therapy for patients with prosthetic aortic valves [8][14]
Choice of agent Target INR Duration of therapy
Mechanical valve and no risk factors for thromboembolism
  • 2.5 (range 2.0–3.0)
  • Lifelong

Mechanical valve and ≥ 1 risk factor for thromboembolism

OR older generation mechanical valves

  • 3.0 (range 2.5–3.5)

Bioprosthetic valve with low risk of bleeding

  • 2.5 (range 2.0–3.0)

NOACs should be avoided in patients with mechanical valves.

Prognosis

  • Asymptomatic patients: Mortality rate is < 1% in a given year. [20]
  • Symptomatic patients: Mortality rate in the first 2 years is > 50% if left untreated. [35]

References

  1. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2). McGraw-Hill Education / Medical ; 2018
  2. Carabello BA, Paulus WJ. Aortic stenosis. The Lancet. 2009; 373 (9667): p.956-966. doi: 10.1016/s0140-6736(09)60211-7 . | Open in Read by QxMD
  3. Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol. 2010; 55 (25): p.2789-2800. doi: 10.1016/j.jacc.2009.12.068 . | Open in Read by QxMD
  4. Osnabrugge RLJ, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: A meta-analysis and modeling study. J Am Coll Cardiol. 2013; 62 (11): p.1002-1012. doi: 10.1016/j.jacc.2013.05.015 . | Open in Read by QxMD
  5. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63 (22): p.e57-185. doi: 10.1016/j.jacc.2014.02.536 . | Open in Read by QxMD
  6. Kasper DL, Fauci AS, Hauser SL, Longo DL, Lameson JL, Loscalzo J. Harrison's Principles of Internal Medicine. McGraw-Hill Education ; 2015
  7. Otto CM. Clinical manifestations and diagnosis of aortic stenosis in adults. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-aortic-stenosis-in-adults.Last updated: October 24, 2016. Accessed: October 4, 2017.
  8. Crawford MH. Current Diagnosis and Treatment: Cardiology. Lange ; 2013
  9. Naqvi TZ. Echocardiography in transcatheter aortic (Core)Valve implantation: Part 2-Transesophageal echocardiography. Echocardiography. 2018; 35 (7): p.1020-1041. doi: 10.1111/echo.14034 . | Open in Read by QxMD
  10. Solberg OG, Ueland T, Wergeland R, et al. High-sensitive troponin T and N-terminal-brain-natriuretic-peptide predict outcome in symptomatic aortic stenosis. Scandinavian Cardiovascular Journal. 2012; 46 (5): p.278-285. doi: 10.3109/14017431.2012.687836 . | Open in Read by QxMD
  11. Røsjø H, Andreassen J, Edvardsen T, Omland T. Prognostic Usefulness of Circulating High-Sensitivity Troponin T in Aortic Stenosis and Relation to Echocardiographic Indexes of Cardiac Function and Anatomy. The American Journal of Cardiology. 2011; 108 (1): p.88-91. doi: 10.1016/j.amjcard.2011.02.346 . | Open in Read by QxMD
  12. Kupari M, Eriksson S, Turto H, Lommi J, Petterson K. Leakage of cardiac troponin I in aortic valve stenosis. Journal of Internal Medicine. 2005; 258 (3): p.231-237. doi: 10.1111/j.1365-2796.2005.01529.x . | Open in Read by QxMD
  13. Nishimura RA, Carabello BA. Hemodynamics in the Cardiac Catheterization Laboratory of the 21st Century. Circulation. 2012; 125 (17): p.2138-2150. doi: 10.1161/circulationaha.111.060319 . | Open in Read by QxMD
  14. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017; 135 (25). doi: 10.1161/cir.0000000000000503 . | Open in Read by QxMD
  15. Clavel M-A, Malouf J, Messika-Zeitoun D, Araoz PA, Michelena HI, Enriquez-Sarano M. Aortic Valve Area Calculation in Aortic Stenosis by CT and Doppler Echocardiography. JACC: Cardiovascular Imaging. 2015; 8 (3): p.248-257. doi: 10.1016/j.jcmg.2015.01.009 . | Open in Read by QxMD
  16. Marquis-Gravel G, Redfors B, Leon MB, Généreux P. Medical Treatment of Aortic Stenosis. Circulation. 2016; 134 (22): p.1766-1784. doi: 10.1161/circulationaha.116.023997 . | Open in Read by QxMD
  17. Kang TS, Park S. Antihypertensive Treatment in Severe Aortic Stenosis. Journal of Cardiovascular Imaging. 2018; 26 (2): p.45. doi: 10.4250/jcvi.2018.26.e9 . | Open in Read by QxMD
  18. Jimenez-Candil J. Effects of angiotensin converting enzyme inhibitors in hypertensive patients with aortic valve stenosis: a drug withdrawal study. Heart. 2005; 91 (10): p.1311-1318. doi: 10.1136/hrt.2004.047233 . | Open in Read by QxMD
  19. Routledge H, Townend J. ACE inhibition in aortic stenosis: dangerous medicine or golden opportunity?. Journal of Human Hypertension. 2001; 15 (10): p.659-667. doi: 10.1038/sj.jhh.1001260 . | Open in Read by QxMD
  20. Pellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622 Adults With Asymptomatic, Hemodynamically Significant Aortic Stenosis During Prolonged Follow-Up. Circulation. 2005; 111 (24): p.3290-3295. doi: 10.1161/circulationaha.104.495903 . | Open in Read by QxMD
  21. Yoon S-H, Schmidt T, Bleiziffer S, et al. Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation. Journal of the American College of Cardiology. 2017; 70 (22): p.2752-2763. doi: 10.1016/j.jacc.2017.10.006 . | Open in Read by QxMD
  22. Franzone A, Pilgrim T, Stortecky S, Windecker S. Evolving Indications for Transcatheter Aortic Valve Interventions. Current Cardiology Reports. 2017; 19 (11). doi: 10.1007/s11886-017-0921-3 . | Open in Read by QxMD
  23. Banovic M, Athithan L, McCann GP. Aortic stenosis and diabetes mellitus: An ominous combination. Diabetes and Vascular Disease Research. 2019; 16 (4): p.310-323. doi: 10.1177/1479164118820657 . | Open in Read by QxMD
  24. Chen RS, Bivens MJ, Grossman SA. Diagnosis and Management of Valvular Heart Disease in Emergency Medicine. Emerg Med Clin North Am. 2011; 29 (4): p.801-810. doi: 10.1016/j.emc.2011.08.001 . | Open in Read by QxMD
  25. Khot UN, Novaro GM, Popović ZB, et al. Nitroprusside in Critically Ill Patients with Left Ventricular Dysfunction and Aortic Stenosis. New England Journal of Medicine. 2003; 348 (18): p.1756-1763. doi: 10.1056/nejmoa022021 . | Open in Read by QxMD
  26. Aksoy O, Yousefzai R, Singh D, et al. Cardiogenic shock in the setting of severe aortic stenosis: role of intra-aortic balloon pump support. Heart. 2010; 97 (10): p.838-843. doi: 10.1136/hrt.2010.206367 . | Open in Read by QxMD
  27. Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis. Circulation. 2009; 119 (11): p.1541-1551. doi: 10.1161/circulationaha.109.191959 . | Open in Read by QxMD
  28. Huang H, Kovach C, Reisman M, et al. TCT-100 Emergency TAVR for Cardiogenic Shock—right heart function and early mechanical circulatory support improve outcomes. Journal of the American College of Cardiology. 2018; 72 (13): p.B43-B44. doi: 10.1016/j.jacc.2018.08.1198 . | Open in Read by QxMD
  29. Masha L, Vemulapalli S, Manandhar P, et al. Demographics, Procedural Characteristics, and Clinical Outcomes When Cardiogenic Shock Precedes TAVR in the United States. Journal of the American College of Cardiology: Cardiovascular Interventions. 2020; 13 (11): p.1314-1325. doi: 10.1016/j.jcin.2020.02.033 . | Open in Read by QxMD
  30. Kolte D, Khera S, Vemulapalli S, et al. Outcomes Following Urgent/Emergent Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology: Cardiovascular Interventions. 2018; 11 (12): p.1175-1185. doi: 10.1016/j.jcin.2018.03.002 . | Open in Read by QxMD
  31. Lieberman EB, Bashore TM, Hermiller JB, et al. Balloon aortic valvuloplasty in adults: Failure of procedure to improve long-term survival. Journal of American College of Cardiology. 1995; 26 (6): p.1522-1528. doi: 10.1016/0735-1097(95)00363-0 . | Open in Read by QxMD
  32. Kolkailah AA, Doukky R, Pelletier MP, Volgman AS, Kaneko T, Nabhan AF. Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis in people with low surgical risk. Cochrane Database of Systematic Reviews. 2019 . doi: 10.1002/14651858.cd013319.pub2 . | Open in Read by QxMD
  33. Virtanen MPO, Eskola M, Jalava MP, et al. Comparison of Outcomes After Transcatheter Aortic Valve Replacement vs Surgical Aortic Valve Replacement Among Patients With Aortic Stenosis at Low Operative Risk. Jorunal of the American Medical Association. 2019; 2 (6): p.e195742. doi: 10.1001/jamanetworkopen.2019.5742 . | Open in Read by QxMD
  34. Kodali SK, Williams MR, Smith CR, et al. Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement. New England Journal of Medicine. 2012; 366 (18): p.1686-1695. doi: 10.1056/nejmoa1200384 . | Open in Read by QxMD
  35. Otto CM, Prendergast B. Aortic-Valve Stenosis — From Patients at Risk to Severe Valve Obstruction. New England Journal of Medicine. 2014; 371 (8): p.744-756. doi: 10.1056/nejmra1313875 . | Open in Read by QxMD
  36. Saikrishnan N, Kumar G, Sawaya FJ, Lerakis S, Yoganathan AP. Accurate assessment of aortic stenosis: a review of diagnostic modalities and hemodynamics. Circulation. 2014; 129 (2): p.244-253. doi: 10.1161/CIRCULATIONAHA.113.002310 . | Open in Read by QxMD
  37. Aortic Stenosis: Pathophysiology, Diagnosis, and Medical Management of Nonsurgical Patients. https://www.ncbi.nlm.nih.gov/pubmed/23547127. Updated: February 13, 2017. Accessed: March 21, 2018.
  38. Ren X. Aortic Stenosis. Aortic Stenosis. New York, NY: WebMD. http://emedicine.medscape.com/article/150638. Updated: December 11, 2016. Accessed: February 26, 2017.
  39. Stritzke J, Linsel-nitschke P, Markus MR, et al. Association between degenerative aortic valve disease and long-term exposure to cardiovascular risk factors: results of the longitudinal population-based KORA/MONICA survey. Eur Heart J. 2009; 30 (16): p.2044-2053. doi: 10.1093/eurheartj/ehp287 . | Open in Read by QxMD
  40. Mohty D, Pislaru S. Valvular heart disease in elderly adults. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/valvular-heart-disease-in-elderly-adults.Last updated: December 22, 2016. Accessed: November 28, 2017.
  41. Van Diepen S, Katz JN, Albert NM, et al. Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation. 2017; 136 (16). doi: 10.1161/cir.0000000000000525 . | Open in Read by QxMD
  42. Grimard BH, Safford RE, Burns EL. Aortic Stenosis: Diagnosis and Treatment.. American Family Physician. 2016; 93 (5): p.371-8.
  43. Bayer MF. Acute pulmonary edema due to stress cardiomyopathy in a patient with aortic stenosis: a case report. Cases Journal. 2009; 2 (1). doi: 10.1186/1757-1626-2-9128 . | Open in Read by QxMD
  44. Yan AT, Koh M, Chan KK, et al. Association Between Cardiovascular Risk Factors and Aortic Stenosis. Journal of the American College of Cardiology. 2017; 69 (12): p.1523-1532. doi: 10.1016/j.jacc.2017.01.025 . | Open in Read by QxMD
  45. Natorska J, Wypasek E, Grudzień G, et al. Does Diabetes Accelerate the Progression of Aortic Stenosis through Enhanced Inflammatory Response within Aortic valves?. Inflammation. 2011; 35 (3): p.834-840. doi: 10.1007/s10753-011-9384-7 . | Open in Read by QxMD
  46. Testuz A, Nguyen V, Mathieu T, et al. Influence of metabolic syndrome and diabetes on progression of calcific aortic valve stenosis. International Journal of Cardiology. 2017; 244 : p.248-253. doi: 10.1016/j.ijcard.2017.06.104 . | Open in Read by QxMD